摘要
随着医学研究的进展,血液肿瘤国际诊疗指南中纳入的基因变异指标越来越多。在2022年更新的多项国际指南中,都进一步强调基因变异对血液肿瘤分型和预后评估的重要性。血液肿瘤的临床诊疗已开始进入精准医学和基因组时代,越来越依赖于高通量测序技术的应用。
As medical research progresses,an increasing number of genetic variations are being incorporated into international guidelines for the diagnosis and treatment of hematological malignancies.In several international guidelines updated in 2022,more emphasis is placed on the importance of genetic variation in the classification and prognosis assessment of hematological malignancies.The clinical diagnosis and treatment of hematological malignancies have entered the era of precision medicine and genomics,relying increasingly on the application of high-throughput sequencing technology.
作者
王芳
陈雪
吴祁生
张阳
刘红星
Wang Fang;Chen Xue;Wu Qisheng;Zhang Yang;Liu Hongxing(Medical Laboratory Division,Hebei Yanda Lu Daopei Hospital,Langfang 065201,China;Laboratory Medicine,Beijing Lu Daopei Hospital,Beijing 100176,China;Molecular Medicine Center,Beijing Lu Daopei Institute of Hematology,Beijing 100176,China)
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2023年第9期888-892,共5页
Chinese Journal of Laboratory Medicine
关键词
血液肿瘤
白血病
基因
突变
基因融合
高通量核苷酸测序
Hematologic neoplasms
Leukemia
Genes
Mutation
Gene fusion
High-throughput nucleotide sequencing
作者简介
通信作者:刘红星,Email:starliu@pku.edu.cn。
